A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials

Paricalcitol, a new vitamin D receptor activator (VDRA), is reported to be more effective than other VDRAs in reducing calcium and phosphorus levels in patients undergoing hemodialysis. However, the efficacy and safety of paricalcitol remain controversial. This analysis compares paricalcitol with ot...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Xinghua, Shi, Ermin, Wang, Shiwei, Song, Yuzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259607/
https://www.ncbi.nlm.nih.gov/pubmed/32470067
http://dx.doi.org/10.1371/journal.pone.0233705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259607/
https://www.ncbi.nlm.nih.gov/pubmed/32470067
http://dx.doi.org/10.1371/journal.pone.0233705

Ejemplares similares